B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases. Journal Abstract

B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases.

Publication Date: 2024 Jun

Full Text Sources

Elsevier Science (Free)

ClinicalKey (Free)

Authors

Aiden Haghikia; Georg Schett; Dimitrios Mougiakakos

Abstract

OBJECTIVE

Neuroimmunology research and development has been marked by substantial advances, particularly in the treatment of neuroimmunological diseases, such as multiple sclerosis, myasthenia gravis, neuromyelitis optica spectrum disorders, and myelin oligodendrocyte glycoprotein antibody disease. With more than 20 drugs approved for multiple sclerosis alone, treatment has become more personalised. The approval of disease-modifying therapies, particularly those targeting B cells, has highlighted the role of immunotherapeutic interventions in the management of these diseases. Despite these successes, challenges remain, particularly for patients who do not respond to conventional therapies, underscoring the need for innovative approaches.

Source

The Lancet. Neurology

Pub Types(s)

Journal Article

Language

English

PubMed ID

38760099